FDA ad­comm votes unan­i­mous­ly in sup­port of a J&J Covid-19 boost­er two months af­ter one-dose shot

The FDA’s Vac­cines and Re­lat­ed Bi­o­log­i­cal Prod­ucts Ad­vi­so­ry Com­mit­tee (VRB­PAC) on Fri­day vot­ed 19-0 in fa­vor of au­tho­riz­ing a sec­ond shot of J&J’s Covid-19 vac­cine to fol­low at least two months af­ter the ini­tial dose.

Reg­u­la­tors don’t have to fol­low VRB­PAC’s rec­om­men­da­tion, but they al­most al­ways do. Con­sid­er­ing that the CDC’s ad­vi­so­ry com­mit­tee has al­ready been set to re­view the ex­pand­ed EUA, VRB­PAC’s rec­om­men­da­tion is like­ly to be adopt­ed.

Jo­han Van Hoof

The vote came af­ter Janssen pre­sent­ed da­ta from mul­ti­ple stud­ies sug­gest­ing a sec­ond shot pro­vides a sig­nif­i­cant boost in ef­fi­ca­cy com­pared to the sin­gle-dose reg­i­men, in­clud­ing one tri­al that demon­strat­ed a rough­ly 94% ef­fi­ca­cy rate against mod­er­ate and se­vere Covid-19 in the US. That com­pares to a 74% US ef­fi­ca­cy rate for the sin­gle shot, ac­cord­ing to Janssen’s fi­nal analy­sis from a sep­a­rate study.

To­day’s meet­ing could have gone a few dif­fer­ent ways, ac­cord­ing to the ini­tial vot­ing ques­tion, which asked ad­comm mem­bers to con­sid­er da­ta sup­port­ing both 2-month and 6-month boost­ers. While a boost at 2 months in­creased an­ti­body titers by 3.5- to 6.2-fold, ac­cord­ing to Janssen’s glob­al ther­a­peu­tic head of vac­cines Jo­han Van Hoof, a 6-month boost sug­gest­ed 9- to 12-fold in­creas­es.

How­ev­er, sev­er­al VRB­PAC mem­bers were con­cerned about the small sam­ple size from the 6-month co­hort, which on­ly had da­ta avail­able from 17 pa­tients.

Paul Of­fit

“Al­though it’s like­ly to be fine, it’s re­al­ly hard to make a de­ci­sion for thou­sands and tens of thou­sands and mil­lions of peo­ple based on 17 peo­ple,” said Paul Of­fit, a VRB­PAC pan­elist and pro­fes­sor of pe­di­atrics at Chil­dren’s Hos­pi­tal of Philadel­phia. “It just seems to me the most log­i­cal thing to do at this point would be to say that a sec­ond dose is rec­om­mend­ed for at least two months lat­er.”

Oth­er ad­comm mem­bers unan­i­mous­ly agreed, de­cid­ing to vote on just the 2-month da­ta for now. Many of them em­pha­sized the ur­gency of a boost­er, not­ing that mil­lions of peo­ple who’ve been vac­ci­nat­ed with a sin­gle dose are at a high­er risk for dis­ease com­pared to those who’ve re­ceived one of the mR­NA vac­cines.

There are da­ta that sug­gest the vac­cine’s ef­fi­ca­cy is even less ro­bust than Janssen sug­gest­ed in their pre­sen­ta­tion, the FDA’s top vac­cine leader Pe­ter Marks added, due to a lack of avail­able da­ta.

“The idea of the Janssen vac­cine as one dose was used as an out­reach vac­cine. Many of the peo­ple who got that may not have been part of a health main­te­nance or­ga­ni­za­tion, or an or­ga­nized health­care sys­tem, so track­ing that may have been chal­leng­ing,” he said.

Aman­da Cohn

Aman­da Cohn, ex­ec­u­tive sec­re­tary of the CDC’s Ad­vi­so­ry Com­mit­tee on Im­mu­niza­tion Prac­tices, said study re­sults dis­cussed at a Sept. 22 ACIP meet­ing sug­gest­ed the Janssen vac­cine was on­ly 68% ef­fec­tive against hos­pi­tal­iza­tions in a group of adults who were not im­muno­com­pro­mised, which is sig­nif­i­cant­ly low­er than the rough­ly 80% ef­fi­ca­cy rate against hos­pi­tal­iza­tions than Janssen re­port­ed from their re­al-world study with Ae­tion.

VRB­PAC mem­ber Archana Chat­ter­jee, who’s dean of the Chica­go Med­ical School and VP of med­ical af­fairs at the Ros­alind Franklin Uni­ver­si­ty of Med­i­cine and Sci­ence, said her ini­tial re­sponse to the vot­ing ques­tion was no.

Archana Chat­ter­jee

“How­ev­er, hav­ing lis­tened to the con­ver­sa­tion, and see­ing the da­ta in its to­tal­i­ty, as well as plac­ing it in the con­text of these 15 mil­lion peo­ple who have been vac­ci­nat­ed with a sin­gle dose and whose im­mu­ni­ty may be wan­ing … This is still a pub­lic health im­per­a­tive,” she said.

Pen­ny Heaton, Janssen’s glob­al ther­a­peu­tic area head of vac­cines, chimed in to spec­i­fy that the sin­gle shot’s re­sponse ap­pears to be durable, though less ef­fec­tive than a two-dose reg­i­men.

Some of the VRB­PAC mem­bers al­so spec­i­fied that they would con­sid­er an­oth­er shot the sec­ond dose in a two-shot reg­i­men, as op­posed to a boost­er.

Pen­ny Heaton

“I think this, frankly, was al­ways a two-dose vac­cine. I think it’s bet­ter as a two-dose vac­cine, it’d be hard to rec­om­mend this as a sin­gle-dose vac­cine at this point, giv­en those two month-da­ta,” Of­fit said.

VRB­PAC al­so vot­ed unan­i­mous­ly yes­ter­day to ex­pand Mod­er­na’s Covid-19 vac­cine EUA for boost­er dos­es for cer­tain high-risk in­di­vid­u­als, just a few weeks af­ter vot­ing to au­tho­rize Pfiz­er’s boost­er for the same pop­u­la­tion. Pan­elist Er­ic Ru­bin, ed­i­tor in chief of the New Eng­land Jour­nal of Med­i­cine and an ex­pert on in­fec­tious dis­eases at Har­vard’s pub­lic health school, not­ed yes­ter­day that while Mod­er­na’s da­ta “are not per­fect,” these are “ex­tra­or­di­nary times” — and ad­comm mem­bers seemed to take the same stance with J&J’s vac­cine.

In a mix-and-match study, par­tic­i­pants who re­ceived J&J’s sin­gle shot fol­lowed by a Mod­er­na shot saw a geo­met­ric mean fold rise (the ra­tio of post-vac­ci­na­tion titer val­ue to pre-vac­ci­na­tion titer val­ue) of 76-fold, ac­cord­ing to Kirsten Lyke of the Cen­ter for Vac­cine De­vel­op­ment and Glob­al Health at the Uni­ver­si­ty of Mary­land School of Med­i­cine. That com­pared to a 4.2 GM­FR in those who re­ceived two dos­es of J&J’s vac­cine, and a 35 GM­FR in those who got J&J’s vac­cine fol­lowed by the Pfiz­er/BioN­Tech vac­cine.

“What I would note is that the neu­tral­iz­ing an­ti­bod­ies did in­crease in re­sponse to any boost re­gard­less of the pri­ma­ry vac­ci­na­tion se­ries,” she said, al­so not­ing that the mR­NA vac­cines re­sult­ed in high­er an­ti­body titers in the first 28 days af­ter the boost.

Ofer Levy, a pro­fes­sor of pe­di­atrics at Har­vard Med­ical School and di­rec­tor of Boston Chil­dren’s Hos­pi­tal’s pre­ci­sion vac­cines pro­gram, ex­pressed con­cern over re­cent re­ports that some Amer­i­cans are tak­ing mat­ters in­to their own hands, re­ceiv­ing unau­tho­rized boost­ers and mix­ing prod­ucts.

“In the re­al world, all these kinds of com­bi­na­tions or ex­tra boost­ers al­ready hap­pen­ing,” he said. “So I think it’s a mat­ter of some ur­gency for FDA to help sort out what is ad­mit­ted­ly a com­pli­cat­ed and chal­leng­ing sce­nario. But we can’t hide from it, and I do think we need to give guid­ance to the pub­lic.”

At the In­flec­tion Point for the Next Gen­er­a­tion of Can­cer Im­munother­a­py

While oncology researchers have long pursued the potential of cellular immunotherapies for the treatment of cancer, it was unclear whether these therapies would ever reach patients due to the complexity of manufacturing and costs of development. Fortunately, the recent successful development and regulatory approval of chimeric antigen receptor-engineered T (CAR-T) cells have demonstrated the significant benefit of these therapies to patients.

Stéphane Bancel, Moderna CEO

'This is not go­ing to be good': Mod­er­na CEO Ban­cel warns of a 'ma­te­r­i­al drop' in vac­cine ef­fi­ca­cy as Omi­cron spreads

Even as public health officials remain guarded about their comments on the likelihood Omicron will escape the reach of the currently approved Covid-19 vaccines, there’s growing scientific consensus that we’re facing a variant that threatens to overwhelm the vaccine barricades that have been erected.

Stéphane Bancel, the CEO of Moderna, one of the leading mRNA players whose quick vault into the markets with a highly effective vaccine created an instant multibillion-dollar market, added his voice to the rising chorus early Tuesday. According to Bancel, there will be a significant drop in efficacy when the average immune system is confronted by Omicron. The only question now is: How much?

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,400+ biopharma pros reading Endpoints daily — and it's free.

With on­ly burns to show in gene ther­a­py, Astel­las inks deal with AAV spe­cial­ist Dyno in push for a bet­ter cap­sid

On the hunt for a better AAV capsid for gene therapy, Eric Kelsic’s Dyno Therapeutics has set itself apart with its focus on machine learning to help speed discovery. Now, Japanese drugmaker Astellas — fresh off a slate of gene therapy burns — is taking a bet on Dyno as it looks to the future.

Astellas and Dyno will work together as part of an R&D pact to develop next-gen AAV vectors for gene therapy using Dyno’s CapsidMap platform directed at skeletal and cardiac muscle, the companies said Wednesday. Under the terms of the deal, Dyno will design AAV capsids for gene therapy, while Astellas will be responsible for conducting preclinical, clinical and commercialization activities for gene therapy product candidates using the capsids.

Philip Dormitzer, new GSK global head of vaccines R&D

Glax­o­SmithK­line poach­es Pfiz­er's vi­ral vac­cines lead in rush to cap­i­tal­ize on fu­ture of mR­NA

GlaxoSmithKline has appointed Philip Dormitzer, formerly chief scientific officer of Pfizer’s viral vaccines unit, as its newest global head of vaccines R&D, looking to leverage one of the leading minds behind Pfizer and BioNTech’s RNA collaboration that led to Covid-19 jab Comirnaty, the British drug giant said Tuesday.

Dormitzer had been with Pfizer for a little more than six years, joining up after a seven-year stint with Novartis, where he reached the role of US head of research and head of global virology for the company’s vaccines and diagnostics unit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,400+ biopharma pros reading Endpoints daily — and it's free.

In­tro­duc­ing End­points Stu­dio, a new way to ad­ver­tise with End­points-craft­ed brand­ing cam­paigns

Since our start in 2016, Endpoints has grown fast while executing our mission to cover biopharma’s most critical developments for industry pros worldwide. As readership has grown, our advertising business has too. Endpoints advertising partners support the mission and engage their desired audiences through announcements on our email and web platforms, brand recognition in our event coverage and sponsorships of Endpoints daily and weekly reports.

Lan Huang, BeyondSpring CEO

Months af­ter shock­ing in­vestors with lung can­cer win, Be­yond­Spring's lead drug hits road­block at the FDA

BeyondSpring shocked investors in early August after its once-marginal lead drug suddenly showed a lot of promise in a common form of lung cancer. With hopes high, the FDA has now slammed the door on that drug in another indication — does that spell bad news for BeyondSpring’s Cinderella story?

The FDA issued BeyondSpring a complete response letter for its plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia, effectively shutting down the drug’s immediate chances at a marketing approval, the biotech said Wednesday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,400+ biopharma pros reading Endpoints daily — and it's free.

J&J and Sanofi's mul­ti­ple myelo­ma tit-for-tat con­tin­ues, as sub­cu­ta­neous Darza­lex wins com­bo ap­proval

J&J and Sanofi have gone back and forth in their multiple myeloma tug-of-war. Earlier this year, Sanofi notched an approval of Sarclisa in combination with Amgen’s Kyprolis to try to outflank the big conglomerate, but J&J is clapping back.

Wednesday afternoon, Amgen announced that the subcutaneous version of J&J’s blockbuster Darzalex is also now approved as a combo with Kyprolis and dexamethasone. The green light came through for adults with relapsed or refractory multiple myeloma who had progressed on one to three earlier lines of therapy.

As first Omi­cron case in US crops up, re­searchers won­der: which an­ti­bod­ies, vac­cines will hold up?

As Covid-19 drug and vaccine developers race to figure out which of their products might be hampered by the new variant, the CDC on Wednesday afternoon announced the first confirmed case of the Omicron variant (B.1.1.529) in the US, found in San Francisco.

The unidentified individual was a traveler who returned from South Africa on Nov. 22, 2021, was fully vaccinated, and had mild symptoms that the CDC described as improving. All close contacts have been contacted and have tested negative, the centers said.

Michael Handley, Statera Biopharma CEO

Stat­era Bio­phar­ma gets the OK to re­sume the study of a po­ten­tial stock­pile drug for lethal ra­di­a­tion ex­po­sure

Last summer, when Cytocom merged with Cleveland BioLabs to grab a spot on Nasdaq, it also inherited an intriguing rare disease program that was under clinical hold. With a new name and brand, the company says it’s ready to bring that program back to the forefront.

The FDA has lifted its clinical hold on entolimod, a toll-like receptor 5 (TLR5) agonist being developed for patients exposed to lethal amounts of radiation, the company — now called Statera Biopharma — announced on Wednesday.